iCoreConnect Expands Patient Education With Integration of iCoreAcademy Videos Into SOTA Cloud Dental Imaging Software
NEWMEDIAWIRE) - iCoreConnect Inc. (NASDAQ: ICCT), a leading provider of cloud-based software and technology solutions has announced the seamless integration of its iCoreAcademy patient education video library with SOTA Cloud, advanced cloud-based dental imaging platform. This collaboration allows dental professionals to access over 120 iCoreAcademy educational videos directly within SOTA Cloud, enabling simultaneous review of patient X-rays or intraoral images while educating patients on their oral health.
Comprehensive Video Library Enhances Patient Education
The video library covers a wide range of topics, from dental conditions and treatment options to detailed procedural explanations, delivering information in a clear, concise format designed to enhance patient understanding and engagement.
'We're excited to integrate iCoreAcademy's powerful educational platform with SOTA Cloud's innovative imaging technology,' said Robert McDermott, President & CEO of iCoreConnect. 'This partnership aligns with our mission to improve patient care by equipping dental practices with tools that foster better communication and understanding.'
Seamless Integration Supports Workflow Efficiency
The integration leverages iCoreConnect's commitment to open APIs and interoperability, ensuring a seamless implementation process. This collaboration highlights iCoreConnect's broader vision of creating interconnected solutions across the dental software landscape, paving the way for future innovations.
Albert Kim, CEO of SOTA Cloud, expressed similar enthusiasm: 'We're proud to offer our users access to iCoreAcademy's robust patient education resources directly within SOTA Cloud. Together, we're empowering dental professionals with tools to elevate patient care and outcomes.'
Unifying Technology and Education for Better Patient Care
iCoreAcademy's video library simplifies complex dental topics, providing patients with accessible insights into conditions, treatments, and procedural codes. SOTA Cloud, renowned for its intuitive cloud-based imaging software, enables dentists to effortlessly acquire, store, and view imaging data from any device, streamlining workflows and enhancing efficiency.
This integration represents a significant step forward in combining cutting-edge dental technology with impactful patient education, fostering a unified platform that helps practices deliver exceptional care.
About iCoreConnect Inc.
iCoreConnect Inc. is a SaaS leader in cloud-based software and technology solutions, designed to enhance workflow productivity and profitability in healthcare.
About SOTA Cloud
SOTA Cloud is revolutionizing dental care with FDA-cleared, cloud-based dental imaging technology that enhances patient outcomes, streamlines operations, and reduces costs. Designed to unify data, technology, and teams, SOTA Cloud integrates seamlessly with imaging modalities, practice management software, EHR systems, and A.I. tools. Scalable for practices of all sizes, SOTA Cloud empowers dental professionals to deliver exceptional care while optimizing efficiency and security.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website, www.sec.gov.
Investor Contacts:
888.810.7706, ext 5
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Kessler Topaz Meltzer & Check, LLP Reminds MicroStrategy Incorporated d/b/a Strategy Investors of Important Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - June 8, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Strategy losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategy investors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Yahoo
an hour ago
- Yahoo
2 High-Growth Stocks to Buy and Hold for Great Long-Term Potential
CoreWeave is a promising stock to use to profit from the growing investment in AI infrastructure services. Axon stock recently hit new highs as it continues to report growing demand for its public safety solutions. 10 stocks we like better than CoreWeave › Investing in fast-growing companies that still have a large opportunity ahead for their products can help you build wealth. Artificial intelligence (AI) and public safety are promising industries to look for investments in 2025. Here are two stocks to ride these megatrends. AI is expected to add trillions in value to the economy over the long term, but this first requires substantial investment in data centers specially designed to handle AI computing workloads. CoreWeave (NASDAQ: CRWV) is a leader in offering AI infrastructure through the cloud for training models and other advanced workloads at scale. CoreWeave's revenue has exploded over the last year, growing from $189 million in Q1 2024 to $982 million in Q1 2025. Management expects 2025 revenue to be between $4.9 billion to $5.1 billion. For a long-term investor, CoreWeave is a unique stock with which to ride the growth of AI. It earns revenue through multiyear contracts or on-demand services, but most of its revenue is through committed contracts. This business model instills steady revenue and growing cash flows over time. The business is in the process of investing in technology to meet growing demand for its services. It reported a loss of $314 million last quarter. This mostly reflects the high upfront investment it's making in infrastructure, such as Nvidia's graphics processing units (GPUs), to offer its AI cloud platform to customers. However, CoreWeave is already showing the potential to be a very profitable business down the road. In Q1, its adjusted operating income increased 17% year over year to $163 million. But until it achieves higher margins, investors should expect the stock to be volatile. This is a world-class AI infrastructure provider that is trading at a price-to-sales multiple of 13 based on management's 2025 guidance. This is based on the company's current market cap (share price times shares outstanding) of $64 billion. Investors buying around this valuation can still expect to earn excellent returns over the next several years. Axon Enterprise (NASDAQ: AXON) (formerly Taser International) started over 30 years ago selling its Taser energy devices for law enforcement and self-defense. In recent years, the company has transformed into a services company with software solutions. This has grown its addressable market to an estimated $129 billion. Axon offers cloud-based evidence gathering software and body cameras, which has transformed the business from a device seller to a comprehensive solutions provider for public safety. Revenue from software and services grew 39% year over year to $263 million last quarter. Taser devices remain a key growth driver for the company. Since launching a few years ago, Taser 10 orders are growing twice as fast as the adoption of Taser 7. This indicates an expanding market for its products, which is a great sign for investors buying shares today. Axon's total revenue grew 31% year over year last quarter to $604 million. Axon is also benefiting from strong demand for Draft One, a service that uses AI to automatically fill out data entries and police reports. It saves hours of time from manual work, which has made it the fastest-growing software offering in Axon's history. Taser is potentially vulnerable to risks that investors should be aware of. It generates some revenue from government contracts, making it susceptible to spending cuts and higher compliance costs that could pressure its profit margin. It could also face public backlash and resistance from privacy concerns over its body camera products. But Axon's history shows that the need for enhanced public safety tools continues to grow. The stock surged to new highs following its first-quarter earnings report, which can be taken as a bullish signal on the company's future. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Ballard has positions in CoreWeave and Nvidia. The Motley Fool has positions in and recommends Axon Enterprise and Nvidia. The Motley Fool has a disclosure policy. 2 High-Growth Stocks to Buy and Hold for Great Long-Term Potential was originally published by The Motley Fool
Business Upturn
2 hours ago
- Business Upturn
URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting Investors have until July 28, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased UroGen securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Cockrell v. UroGen Pharma Ltd., et al. , No. 3:25-cv-06088. Why was UroGen Sued for Securities Fraud? UroGen develops treatments for specialty cancers. The Company's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. One of the Phase 3 trials for UGN-102 is named ENVISION. As alleged, UroGen stated that the ENVISION trial met its primary endpoint and that UroGen had reached 'agreement with the FDA' that the ENVISION trial would support an NDA submission. In truth, the FDA had previously expressed significant concerns to UroGen regarding the ENVISION trial, which lacked a concurrent control arm. The Stock Declines as the Truth is Revealed On May 16, 2025, the FDA published a briefing document stating that it doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. FDA stated that because 'ENVISION lacked a concurrent control arm,' the primary endpoints were 'difficult to interpret' and that UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock declined $2.54 per share, or nearly 26%, from a closing price of $9.85 per share on May 15, 2025, to $7.31 per share on May 16, 2025. Then, on May 21, 2025, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk profile of UGN-102 was not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock declined $3.37 per share, or nearly 45%, from a closing price of $7.54 per share on May 20, 2025, to $4.17 per share on May 21, 2025. Click here if you suffered losses: What Can You Do? If you invested in UroGen you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
